Linezolid-d3 is intended for use as an internal standard for the quantification of linezolid by GC- or LC-MS. Linezolid is a synthetic oxazolidinone antibiotic with activity against a wide range of Gram-positive bacteria, including resistant strains of several species, such as methicillin-resistant S. aureus (MRSA), penicillin-resistant pneumococci, vancomycin-resistant enterococci, various anaerobic bacteria, and several mycobacteria and streptococci (MICs = 2-4 mg/ml).1 Linezolid inhibits protein synthesis by binding to domain V of the 23S ribosomal RNA of the 50S subunit of bacterial ribosomes. In vivo, linezolid (50 mg/kg) reduces pulmonary MRSA load in spontaneously breathing and mechanically ventilated rabbits.2 Formulations containing linezolid have been used to treat MRSA infections.
1.Ager, S., and Gould, K.Clinical update on linezolid in the treatment of gram-positive bacterial infectionsInfect. Drug Resist.587-102(2012) 2.Pauchard, L.A., Blot, M., Bruyere, T., et al.Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilationPLoS One12(11)e0187187(2017)